‘Plan­ning to vac­ci­nate every­one in the US,’ Mod­er­na out­lines ef­forts to sup­ply their Covid-19 vac­cine as man­u­fac­tur­ing ramps up ahead of PhI­II

Twelve days from the planned start of their Phase III piv­otal tri­al, the ex­ec­u­tive crew at Mod­er­na has set up the man­u­fac­tur­ing base need­ed to be­gin pro­duc­tion of the first 500,000 dos­es of their Covid-19 vac­cine with plans to feed it in­to a glob­al sup­ply chain. But the ini­tial batch­es will like­ly be ready in the US first, where com­pa­ny CEO Stéphane Ban­cel plans to be able to vac­ci­nate every­one.

“We have start­ed mak­ing com­mer­cial prod­uct at-risk, and will con­tin­ue to do so every day and every week of the month,” Ban­cel told an­a­lysts dur­ing their morn­ing call on the Phase I da­ta just pub­lished in the New Eng­land Jour­nal of Med­i­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER